AIV Logo AIV Assistant

Loading...

 Logo Bausch Health Companies Inc. - BHC Open Bausch Health Companies Inc. in new tab

6.61
P/E
23.85
EPS
0.26
P/B
-3.00
Beta
0.43

6.6100

6.610

Daily: +12.03%
Key Metrics

Earnings date: Feb. 17, 2026

P/E: 23.85

EPS: 0.26

Book Value: -2.07

Price to Book: -3.00

Debt/Equity: 14787.76

% Insiders: 0.108%

Growth

Revenue Growth: 0.05%

Earnings Growth: 13.68%

Estimates

Forward P/E: 1.41

Forward EPS: 4.41

 Logo About Bausch Health Companies Inc. - (BHC)

Country: Canada

Sector: Health Care

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion